Ultrasonographic assessment of the extent of hepatic steatosis in severe malnutrition

J F Doherty, E J Adam, G E Griffin, M H N Golden

Abstract
Ultrasonographic, blinded assessment was made of the extent of hepatic steatosis in 55 children with severe malnutrition: undernutrition (n=6), marasmus (n=18), marasmic-kwashiorkor (n=17), and kwashiorkor (n=14). The children were examined on admission, in early recovery (considered as baseline), and again at discharge. Eleven healthy control children and eight of the previously malnourished children were studied as comparison groups.

Both oedematous and non-oedematous malnourished children had significantly more steatosis than the comparison groups at each time. Children with oedematous malnutrition had significantly greater steatosis than non-oedematous children at admission. Half of the non-oedematous malnourished children had appreciable hepatic steatosis at both admission and at baseline.

Hepatic fat was only slowly mobilised. The rate constant was 1.4±0.3%/day. One quarter of the children did not change steatosis grades during the period they were in hospital. There was no overall correlation between the extent of steatosis and liver size.

Hepatic steatosis in childhood malnutrition is not confined to oedematous children: it is frequently present in marasmic and undernourished children. Its extent is not necessarily related to the degree of hepatomegaly and accumulated lipid is only slowly mobilised.

Subjects and methods
STUDY CHILDREN
The study group comprised 55 children, 6 to 36 months old. They were consecutively admitted to the Tropical Metabolism Research Unit in Kingston, Jamaica, as a result of severe, primary malnutrition. A summary of their clinical details and diagnoses, using the Wellcome classification, is given in table 1. The children were treated by standard protocols. Their diet was based on an infant formula (Pelargon, Nestlé)

Table 1 The clinical details of the study children; values are mean (SD)

<table>
<thead>
<tr>
<th></th>
<th>Undernutrition (n=6)</th>
<th>Marasmus (n=18)</th>
<th>Marasmic-kwashiorkor (n=17)</th>
<th>Kwashiorkor (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (months)</td>
<td>18-6 (4)</td>
<td>16-7 (6-8)</td>
<td>12-3 (6-3)</td>
<td>12-8 (3-1)</td>
</tr>
<tr>
<td>Admission height for age (Z)</td>
<td>-2.7 (1.5)</td>
<td>-4.2 (1.6)</td>
<td>-4.2 (1.2)</td>
<td>-2.1 (1.0)</td>
</tr>
<tr>
<td>Admission weight for height (Z)</td>
<td>-2.5 (1.1)</td>
<td>-3.0 (0.7)</td>
<td>-2.2 (1.0)</td>
<td>-1.6 (0.9)</td>
</tr>
<tr>
<td>Discharge weight for height (Z)</td>
<td>+0.1 (0.6)</td>
<td>-0.6 (0.7)</td>
<td>+0.1 (0.5)</td>
<td>+0.1 (0.6)</td>
</tr>
<tr>
<td>Time admission to baseline study (days)</td>
<td>11 (3)</td>
<td>8 (3)</td>
<td>9 (2)</td>
<td>13 (6)</td>
</tr>
<tr>
<td>Time baseline to discharge study (days)</td>
<td>29 (10)</td>
<td>34 (10)</td>
<td>26 (11)</td>
<td>26 (7)</td>
</tr>
</tbody>
</table>

Z=SD scores from the NCHS standard height of a child of the same age and weight for a child of the same height.
Ultrasonographic assessment of the extent of hepatic steatosis in severe malnutrition

fortified with vegetable oil (corn or coconut) to give an energy density of 5.7 MJ/kg, vitamins, and minerals.13

COMPARISON GROUPS

Eleven children who were resident in a local children’s home were studied as a control group. Eight previously malnourished children, who had had grade 0 or 1 steatosis at discharge, were also studied between 32 and 162 days after discharge, as a further comparison group. Each of these children was assessed as clinically healthy; they were anthropometrically within 1 SD of the median weight of a child of the same height and sex (National Center for Health Statistics (NCHS) standards).

CONSENT

Informed consent was obtained from each child’s parent or guardian. The study was approved by the ethics committees of the University of the West Indies and of the Ministry of Health, Jamaica.

ULTRASOUND PROCEDURE

Each study child had ultrasonography performed on three occasions:

(1) Within 48 hours of admission (admission);
(2) As soon as the acute signs of malnutrition had resolved but the child had not yet gained any appreciable weight (baseline). This was defined as the first point in time at which the children were oedema free and had gained weight at a rate of 5 g/kg/day, for three consecutive days.
(3) Once the child had regained weight to within 1 SD of the median weight of a child of the same sex and height (NCHS standards) and had spontaneously reduced its appetite so that it was gaining weight at a normal rate (discharge).

Control children were studied once.

On each occasion, ultrasonic ultrasonography was performed using an Ultramark IV machine (Advanced Technology Laboratories) with a 5 MHz probe, by the same investigator (JFD). Photographic prints were obtained at each study; these were randomly coded, shuffled, and sent to England. The extent of hepatic steatosis was assessed from the coded prints alone, independently and blindly with respect to the child’s diagnosis and the stage of recovery at which the study was performed, by a single assessor (EFA). The assessment was based on previously published criteria,10 modified to provide a numerical severity score. This ranged from 0 = normal to 5 = very severe. Mild steatosis was recognised by a slight increase in liver echogenicity and a slight exaggeration of the echo discrepancy between liver and kidney (grade 1). Moderate steatosis was accompanied by loss of echoes from the walls of the portal veins, resulting in a featureless appearance, with a degree of posterior beam attenuation and a greater discrepancy between the liver and kidney echo pattern (grade 2). Very severe steatosis was determined by a still greater degree of posterior beam attenuation, loss of echoes from most of the portal vein, and a marked discrepancy between liver and kidney (grade 5)10; grades 2 and 4 had intermediate appearances.

Assessment of liver size was made by measuring the liver span, in the mid-clavicular line, using ultrasonographically determined surface markers. This measurement was standardised by expressing liver span as a percentage of body length. Span was not recorded in the control children.

STATISTICAL ANALYSIS

Statistical analysis was performed using the Systat Software package (Systat Inc). Non-parametric statistics (Kruskal-Wallis and Friedman analysis of variance (ANOVA) and Mann-Whitney tests) were used for comparison of the degree of hepatic steatosis, as the severity score is not a continuous variable. Parametric statistics (ANOVA) were used for analysis of the liver span data after testing for normality.

A smoothing algorithm14 was used to assess the rate of disappearance of liver fat graphically; the program fits a line through a set of points using distance weighted least squares quadratic regression. A tension of 0.1 was used. The resulting lines are similar to those produced by the method of Cleveland.15

Results

STUDY CHILDREN

Children without oedema (undernutrition and marasmus) were older than the oedematous (marasmic-kwashiorkor and kwashiorkor) children (p<0.05), and a higher proportion were male (table 1). The undernourished children were not as stunted as the marasmic children: however, they were just as wasted (deficit in weight-for-height); this indicates that the two non-oedematous groups had had similar recent nutritional insults. The times between the three studies were not different among the groups.

All three assessments were made on 51 of the 55 children: one child was considered too ill for ultrasonography to be performed at admission; two children died (one with marasmic-kwashiorkor after the admission, the other, with kwashiorkor, after the admission and baseline study); one child was inadvertently discharged before the final ultrasound.

HEPATIC STEATOSIS

The results are shown in fig 1. Control subjects, with one exception, had a steatosis grade of 0 or 1. The exception was a 16 month old boy, resident in the children’s home, who was assessed as having grade 2 steatosis. Clinical examination of the child and conventional liver function tests were normal. The previously malnourished children, studied at follow up also had either grade 0 or grade 1 steatosis.

At admission 51 of the 54 children had evidence of fat in their livers: the one child who was too ill for assessment, at this time, had grade 5 steatosis at baseline. For each of the diagnoses, at both admission and baseline, the extent of
hepatic steatosis was significantly greater than the controls (fig 1) (p<0.01). The extent of hepatic steatosis was different within the four groups, at each stage of the study (p<0.02). The grade was greater in children with oedematous malnutrition than non-oedematous and greater in those with kwashiorkor than those with marasmic-kwashiorkor (p<0.0001). Children without oedema, however, had appreciable hepatic steatosis (fig 1). Eight of 17 children with marasmus and three of six with undernutrition had an hepatic ultrasound severity score ≥2 both at admission and at baseline.

RECOVERY OF FATTY LIVER

Figure 2 shows the distance weighted least squares quadratic regression lines of the hepatic steatosis grade, with time from admission, by diagnosis. Over the time of observation there was a gradual reduction in the fat score, so that by discharge there were significantly lower scores (p<0.01) in each category (fig 1). However, only three of 29 children with an admission diagnosis of oedematous malnutrition and eight of 22 with previous non-oedematous malnutrition had attained a score of 0 by discharge. Furthermore, about one quarter of both the oedematous (seven of 29) and non-oedematous children (five of 22) had the same score (≥2) at baseline and at discharge; during rehabilitation, these children had not mobilised sufficient fat to alter the abnormal ultrasonographic appearance of their livers. If the intervals between the severity grades are approximately equal and the mobilisation of fat is exponential, then a rate constant (K) for mobilisation of liver fat can be calculated for each of the children that had a score of greater than 0 at discharge. These constants, calculated between baseline and discharge, are shown in table 2. Overall only 1·4% of the liver fat was mobilised each day. There were no statistical differences between the rate constants of any of the diagnostic categories.

LIVER SPAN

The liver span was about 1 cm larger in oedematous than non-oedematous children at both admission and baseline; these differences were significant (table 3). There was no significant effect of time of study on the liver span and no interaction between time and diagnosis. Overall, there was no relationship between the degree of hepatic steatosis and the size of the liver. When the different time points were analysed separately there was a weak positive correlation between the liver span and the degree of hepatic steatosis at admission (Spearman's rho=0·308, p<0·05); the relationship was not significant at baseline or discharge.

Table 2 Rate of mobilisation of liver fat during recovery from malnutrition; values are mean (SEM)

<table>
<thead>
<tr>
<th>Group</th>
<th>No in group</th>
<th>Rate constant (day⁻¹) baseline to discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Undernutrition</td>
<td>3</td>
<td>0·013</td>
</tr>
<tr>
<td>Marasmus</td>
<td>12</td>
<td>0·008 (0·004)</td>
</tr>
<tr>
<td>Marasmic-kwashiorkor</td>
<td>11</td>
<td>0·019 (0·007)</td>
</tr>
<tr>
<td>Kwashiorkor</td>
<td>13</td>
<td>0·016 (0·005)</td>
</tr>
<tr>
<td>Non-oedematous</td>
<td>15</td>
<td>0·009 (0·004)</td>
</tr>
<tr>
<td>Oedematous</td>
<td>24</td>
<td>0·017 (0·004)</td>
</tr>
<tr>
<td>All patients</td>
<td>39</td>
<td>0·014 (0·003)</td>
</tr>
</tbody>
</table>

None of the groups were significantly different.

Table 3 Liver size* in malnourished children; values are mean (SD)

<table>
<thead>
<tr>
<th></th>
<th>Undernutrition (n=6)</th>
<th>Marasmus (n=18)</th>
<th>Marasmic-kwashiorkor (n=17)</th>
<th>Kwashiorkor (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admission</td>
<td>8·1 (2·3)</td>
<td>8·1 (1·3)</td>
<td>8·9 (2·1)</td>
<td>9·5 (1·8)</td>
</tr>
<tr>
<td>Base line</td>
<td>8·2 (0·9)</td>
<td>7·8 (1·0)</td>
<td>8·5 (1·7)</td>
<td>9·2 (1·1)</td>
</tr>
<tr>
<td>Discharge</td>
<td>9·2 (1·2)</td>
<td>7·6 (1·3)</td>
<td>8·3 (1·1)</td>
<td>8·3 (1·0)</td>
</tr>
</tbody>
</table>

*Liver size measured as liver span (cm) x 100/height of child (cm).
Discussion

The precise pathogenesis of fatty liver is unknown. Several theories to explain its occurrence in kwashiorkor have been proposed: endocrine abnormalities,\(^1\) increased fat synthesis,\(^3\) redistribution from adipose tissue,\(^7\) reduced lipoprotein synthesis,\(^8\) \(^9\) abnormalities of lipoprotein lipase,\(^10\) and peroxisomal dysfunction;\(^11\) each have been put forward as playing a part. If the child recovers the fat disappears apparently without any long term sequelae.\(^2\)

The extent of liver fat in the present population was not measured directly; however, the cases were similar to those studied by Waterlow in whom the median amount of fat was about 30\textendash}35\% of total liver wet weight.\(^2\) The distribution of his cases in \(^9\%\) fat classes and of our cases into grades was also similar. Thus, we would anticipate our grade 4 to correspond to Waterlow's 30\textendash}40\% fat and our grade 5 to more than 40\% fat. Although this is an assumed correspondence between the grades and chemical composition, the extent of liver fat in these children is likely to be much greater than in the adult population in which the method was quantitatively validated. Nevertheless, our assessment was made in a masked fashion by an experienced ultrasonographer who had no knowledge of the subjects.

The study confirms the frequency of fatty liver in children with oedematous malnutrition, although there are a few oedematous children without appreciable fatty liver (3\textendash}6\%). However, our results also show that fatty liver is usually present in marasmus and undernutrition\textendash}non\-oedematous forms of malnutrition. In the Wellcome classification of malnutrition,\(^11\) nutritional oedema is \\textit{equated} with kwashiorkor; however, fatty liver is part of the \textit{clinical syndrome} of kwashiorkor.\(^1\) The finding, that fatty liver is frequently present in marasmus, blurs the differences between the Wellcome definitions of kwashiorkor and marasmus. Clearly, the Wellcome classification is useful, among other things, for studies of the pathogenesis of oedema whereas it is misleading if used for studies of the pathogenesis of fatty liver.

The rate of clearance of the fat in the liver was remarkably slow, with up to one quarter of children not apparently metabolising any of the fat in their livers during recovery. Our figure of 1\textendash}4\%/day is in broad agreement with Waterlow's two estimates of 5\textendash}5\%\%/day and 0\textendash}9\%\%/day, using different assumptions. If a 7 kg child has a 400 g liver, with 35\% wet weight as fat (20 g hepatic fat/kg) and he mobilises 1\%/day then only 10\textendash}6 kJ/kg/day (2\textendash}5 kcal) is coming from hepatic fat. Even if the higher of Waterlow's estimates is used, less than 40 kJ/kg/day is supplied from hepatic fat. This is a relatively tiny fraction of the energy consumption of these children, who become markedly hypermetabolic during their period of rapid weight gain.\(^23\)

Their dietary energy supply is closely related to their rate of recovery,\(^24\) and the children frequently consume 800 kJ/kg/day with 60\% of this energy coming from fat; thus, children may oxidise 13 g fat/kg/day.\(^25\) Clearly, during recovery, they do not have a metabolic constraint on fat oxidation. Equally, the children increase their plasma lipoproteins within three to five days of admission to supranormal concentrations\(^26\); there does not seem to be a difficulty with lipoprotein synthesis during recovery. Under these circumstances, one would expect the fat in the liver to be rapidly consumed. However, our data, and those of Waterlow\(^12\) indicate that the fat is mobilised slowly. The defects that form the bases for the current theories of the pathogenesis of fatty liver in malnutrition are quickly corrected during recovery from malnutrition: they are inadequate to explain the phenomenon of persistent hepatic steatosis.

There was no overall association between liver size and liver fat despite the extensive steatosis at each stage of recovery. Our results emphasise that there is often severe fatty liver in malnutrition without significant hepatomegaly. Ultrasound can be used non-invasively and repeatedly to assess fatty liver in further studies of malnutrition. Ethical constraints preclude the use of liver biopsy in children that are relatively well. No data exist, therefore, on the extent of fat in the liver of 'normal' and mild or moderately malnourished children in developing countries. Our results show that fatty liver occurs in undernourished children and even in one of our control children, despite normal liver function tests. It is possible that the prevalence of fatty liver in children in the developing world is greater than is generally believed.

This work was supported by the Wellcome Trust. We are grateful to Professor G Sejeant, MRC Sickle Cell Laboratories, University of the West Indies for allowing us access to the ultrasound machine and to Dr H Mohammed for his help. Drs R Wilkes and D T Simson gave valuable statistical advice.

Methotrexate for severe asthma

Despite the major advances in the treatment of asthma that have been made in the last quarter of a century or so there are still some patients who have severe and even life threatening asthma, although receiving maximal current conventional therapy, and others who suffer the ill effects of regular high dose steroid treatment. Can anything else be done to help such patients? There have been reports of improvement in adults with severe asthma after treatment with methotrexate and a recent paper from Kansas City, Missouri (Salomon Guss and Jay Portnoy, Pediatrics 1992;89: 635–9) gives details of a small uncontrolled trial in children.

Five girls and two boys aged between 3 and 14 years were treated. All had severe asthma and were receiving regular oral prednisone in doses ranging from 30 mg on alternate days to 60 mg daily in addition to inhaled treatment with salbutamol, sodium cromoglicate, and beclomethasone, and oral theophylline. Two of the seven patients had frequent emergency department visits and hospital admissions but one of them was thought to be non-compliant with treatment. Methotrexate was given in a starting dose of 2.5 mg once a week and the dose was increased by 2.5 mg every four weeks to a maximum of 17.5 mg in two patients, 12.5 mg in three, and 7.5 mg in one. One patient was unable to tolerate the drug and had only two doses.

No patient showed any improvement in the asthma in the first three months of methotrexate treatment but eventually three patients came off steroids and two were able to take a much reduced dose. Data are provided about spirometric measurements before and during treatment but they are difficult to interpret because we are not told when the values given were obtained and whether they represent an average over a period of time or single recordings. One patient showed no response after treatment for six months. One 9 year old had all her treatment stopped by her family when her asthma improved after four months of methotrexate. Two children apparently deteriorated and improved again when the course of methotrexate was interrupted and restarted.

The authors try very hard, in my opinion too hard, to make a case for methotrexate. They emphasise the toxicity of steroids in comparison with methotrexate in a quite arbitrary fashion and their assessment of their results does not seem to be totally unbiased. For instance they claim that methotrexate led to fewer emergency visits and admissions to hospital when it is quite clear from their data that there was no significant effect in these respects. They point out in high falutin terms that the study was uncontrolled and therefore the value of the drug remains uncertain but they encourage doctors to try the drug on a ‘give it and see’ basis. There is serious concern about the potential toxicity of methotrexate with pneumonitis, pulmonary fibrosis, and hepatic fibrosis being the main worries. In the present state of knowledge it seems to me that to encourage anything other than a strictly monitored controlled trial would be hard to justify. As far as treating individual patients is concerned, if there is a flag indicating ‘proceed with extreme caution’ it would seem appropriate to wave it vigorously at this point.